SIRP alpha

SIRP alpha

SIRP alpha Overview

Molecule Name
Signal-regulatory protein alpha
Synonyms
SHPS1,SIRPA,CD172A,BIT,MFR,MYD1,P84,PTPNS1
Drug Development Progress
Drugs in Clinical Trials19
Approved Drugs2
Highest Development StageApproved
Target Synonym
SHPS-1,Macrophage fusion receptor,Brain Ig-like molecule with tyrosine-based activation motifs,MFR,Signal-regulatory protein alpha-1,Signal-regulatory protein alpha-2,CD172a,MyD-1 antigen,Sirp-alpha-3,MYD1,SIRPA,Signal Regulatory Protein Alpha,CD172 Antigen-Like Family Member A,Inhibitory Receptor SHPS-1,PTPNS1,SHPS1,SIRP,P84,Brain-Immunoglobulin-Like Molecule With Tyrosine-Based Activation Motifs,Protein Tyrosine Phosphatase, Non-Receptor Type Substrate 1,Tyrosine-Protein Phosphatase Non-Receptor Type Substrate 1,Tyrosine Phosphatase SHP Substrate 1,Signal-Regulatory Protein Alpha-3,Signal-Regulatory Protein Alpha,SHP Substrate 1,CD172a Antigen,Sirp-Alpha-1,Sirp-Alpha-2,MYD-1,Bit,SIRPalpha,SIRPalpha2
Background
Tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS1) is also known as CD172 antigen-like family member A (CD172a), Macrophage fusion receptor, MyD-1 antigen, Signal-regulatory protein alpha (SIRPA or SIRP alpha) or p84, is a member of the SIRP family, and also belongs to the immunoglobulin superfamily. SIRP alpha is Ubiquitous and highly expressed in brain. SIRPA / CD172a is immunoglobulin-like cell surface receptor for CD47 and acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. SIRPA / SHPS-1 supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment and may play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. SIRPA / MyD1 involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin and mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells.

SIRP alpha Product List

Species
  • Human(8)
  • Mouse(6)
  • Cynomolgus(4)
  • Rat(1)
Tag
  • Fc Tag(5)
  • His Tag(4)
  • Fc Tag & Avi Tag(3)
  • His Tag & Avi Tag(3)
  • Mouse IgG Fc Tag(2)
  • Llama IgG Fc Tag(1)
  • Mouse IgG Fc Tag & Avi Tag(1)
Host
  • HEK293(19)
Conjugate
  • Unconjugated(10)
  • Biotin-labeled(7)
  • PE Labeled(2)
Grade
  • RUO(19)
Low Endotoxin
  • Yes(5)
  • No(14)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
SIRP alpha
Human SIRP alpha / CD172a Protein, His Tag, low endotoxin (MALS & BLI verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$350.00

100ug
SIRP alpha
HOTAvitag
SIA-H82A3
Biotinylated Human SIRP alpha / CD172a Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

25ug
SIRP alpha
Mouse SIRP alpha / CD172a Protein, His Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISASPR

$340.00

100ug
SIRP alpha
HOTAvitag
SIA-H82E0
Biotinylated Human SIRP alpha / CD172a Protein, His,Avitag™ (HPLC verified)
Human
HEK293
HPLCSDS-PAGE
ELISA

$360.00

25ug
SIRP alpha
PE-Labeled Human SIRP alpha / CD172a Protein, Fc Tag (recommended for neutralizing assay) (Site-specific conjugation)
Human
HEK293
Flow

$355.00

50tests
SIRP alpha
Avitag
CDA-H82F2
Biotinylated Human SIRP alpha / CD172a Protein, Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

25ug
SIRP alpha
Cynomolgus SIRP alpha / CD172a Protein, Fc Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
SIRP alpha
Cynomolgus SIRP alpha / CD172a Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$340.00

100ug
SIRP alpha
Avitag
SIA-C82E2
Biotinylated Cynomolgus SIRP alpha / CD172a Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
SIRP alpha
Avitag
SIA-C82F3
Biotinylated Cynomolgus SIRP alpha / CD172a Protein, Fc,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
You Have Viewed 1-10 Of 19 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IpsoprubartELA-026Phase 3 ClinicalElectra Therapeutics Inc
Lymphohistiocytosis, Hemophagocytic; Neoplasms
Details
LM-101LM-101Phase 2 ClinicalLaNova Medicines Ltd
Hematologic Neoplasms; Leukemia; Neoplasms; Solid tumours
Details
HX-044HX044; HX-044Phase 2 ClinicalHanx Biopharmaceuticals Pty Ltd
Lymphoma; Solid tumours
Details
BRB-002BRB-002Phase 2 ClinicalBitterroot Bio Inc
Atherosclerosis; Cardiovascular Diseases; Vasculitis
Details
BI-770371BI-770371Phase 2 ClinicalOse Immunotherapeutics
Carcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
IBC-0966IBC-0966Phase 2 Clinical
Neoplasms
Details
HX-009HX-009; HX009-II-02Phase 2 ClinicalWaterstone Hanxbio Pty Ltd
Bile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
BI-765063OSE-172; BI-765063; Effi-DEMPhase 1 ClinicalEffimune
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ADU-1805ADU-1805Phase 1 ClinicalAduro Biotech Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours
Details
Q-1801Q-1801; Q 1801Phase 1 ClinicalQure Biotechnology (Shanghai) Co Ltd
Solid tumours
Details
Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo)DS-1103aPhase 1 ClinicalDaiichi Sankyo Co Ltd
Breast Neoplasms; Solid tumours
Details
JY-47JY47; JY-47Phase 1 ClinicalHangzhou Jiuyuan Gene Biomedical Co Ltd
Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours
Details
BYON-4228BYON-4228Phase 1 ClinicalSanquin Blood Supply Foundation
Lymphoma; Solid tumours
Details
BSI-082BSI-082Phase 1 ClinicalBiosion Inc
Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours
Details
BR-105BR-105; BR105Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd
Lymphoma, Large B-Cell, Diffuse; Neoplasms
Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim)Phase 1 ClinicalBoehringer Ingelheim Corp
Carcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2928TQB-2928Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours
Details
BI-765080Phase 1 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Details
ES-004ES-004; ES 004-N4; ES 004-B4Phase 1 ClinicalElpiscience (Shanghai) Biopharma Ltd
Neoplasms; Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Relugolix/Estradiol/Norethindrone AcetateE2/NETAApprovedMyovant SciencesMYFEMBREE, RYEQOUnited StatesMenorrhagia; LeiomyomaSumitomo Pharma America Inc, Myovant Sciences2021-05-26
Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms
Details
Elagolix/estradiol/norethindrone acetateApprovedAbbvie IncOriahnnUnited StatesMenorrhagiaAbbvie Inc2020-05-29
Menorrhagia
Details
Customer Reviews
  • K***n2026-09-10
    We purchased SIRPA for use as a positive control in binding assays. The product was easy to reconstitute and worked as advertised. We observed a strong, specific signal.
  • R***n2024-06-03
    I recently used the PE-Labeled Human SIRP alpha / CD172a Protein, Fc Tag for detecting the expression of CD47 in Jurkat T-cells and primary T-cells, and I am very pleased with the results. The SIRP alpha reagent effectively binds to CD47 overexpressed in both Jurkat and primary T-cells. This experiment was conducted to demonstrate the overexpression of CD47 in T-cells, using the anti-CD47 antibody (clone: CC2C6) to confirm the expression. Additionally, it was crucial to show that our CD47 can bind to its natural ligand, SIRP alpha. The reagent performed excellently in this regard, providing clear and reliable results. I've attached an image showing the data with a CD47 KO Jurkat cell line, further validating the specificity and effectiveness of this reagent. Overall, I highly recommend this product for CD47 detection and binding studies.
  • J***r2022-08-18
    I used this SIRPa-PE Fc tag for a FACS assay using the recommended SOP provided by Acro and our rep Nik Kamachi. Nik was very helpful in providing insight on the capabilities of Acro to provide custom labeled SIRPa Fc tags to meet our needs for small molecule screening assays that are FACS and IF-based. The human SIRPa-PE Fc tag was very easy to use and gave a strong signal with both flow cytometry and imaging
  • M***g2022-05-07
    We purchased the SIRP-alpha-Fc protein for CD47 competition studies via BLI. The protein was delivered quickly and easy to resuspend following the instructions in the COA. We observed strong binding for this protein to CD47 and minimal background binding to the sensors. We were also able to demonstrate competition with commercially available antibodies. Overall, this product specifically binds CD47 and worked well in BLI based competition assays.
  • 1***42019-10-11
    We purchased the CD172 protein and used it for bioactivity test in our QC release process. The delivery was very fast, and it's easy for storage too. This protein is stable.
  • 1***52019-10-11
    The CD172 protein we purchased was used for the QC release of our CD47 related products. There was slight difference in bioactivity among batches, but the experiments results were stable. The products delivery was quite fast.